Children’s Oncology Group AALL0434: A Phase III Randomized Clinical Trial Testing Nelarabine in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia

RCT (n=659) found that the addition of nelarabine to augmented Berlin-Frankfurt-Muenster (ABFM) regimen improved disease-free survival for children and young adults (88.2% vs. 82.1%; p=0.029), without increased toxicity.

Source:

Journal of Clinical Oncology